Lv5
1080 积分 2024-03-13 加入
Modulating energy metabolism to treat non-obstructive hypertrophic cardiomyopathy? Insights from IMPROVE-HCM
2个月前
已关闭
Sustained Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy: Long-term Assessment Using AI-ECG and Echocardiographic Data
2个月前
已完结
Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
2个月前
已完结
Association between lipoprotein(a) and ischemic stroke: Fibrinogen as a mediator
2个月前
已完结
Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period
5个月前
已完结
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
5个月前
已完结
Family Screening in Hypertrophic Cardiomyopathy
5个月前
已完结
Transcatheter Myotomy for Hypertrophic Obstructive Cardiomyopathy
5个月前
已完结
Myocardial Disarray and Fibrosis across Hypertrophic Cardiomyopathy Stages Associate with ECG Markers of Arrhythmic Risk
5个月前
已关闭
Prognostic value of right ventricular involvement in hypertrophic cardiomyopathy: A systematic review and meta-analysis
5个月前
已完结
皖公网安备34019202002308
